An easy, precise, speci ic, and accurate UPLC method for the quanti ication of emtricitabine (ETC), tenofovir (TFR), and efavirenz (EVR) in their tablet dosage form was developed and validated. ETC, TFR, and EVR were separated and estimated using Waters UPLC with HSS C18 (100 × 3 mm, 1.7 µ) column. The mobile phase was 0.01 N potassium dihydrogen phosphate buffer (pH 4.5) and acetonitrile (40:60, vol/vol). The elution of ETC, TFR, and EVR was achieved using low rate at 0.4 ml/min and detected at 265 nm using a photodiode array detector. The detector response was linear from 75 to 450 µg/ml for TNF, 50 to 300 µg/ml for ETC, and 150 to 900 µg/ml for EVR. The limit of detection and limit of quanti ication were 0.601 µg/ml and 1.82 µg/ml, 0.330 µg/ml and 0.100 µg/ml, 0.911 µg/ml and 2.76 µg/ml for TNF, ETC and EVR respectively. Validation was carried out in compliance with ICH guidelines. It was noticed that all validation parameters were inside the permissible range.
INTRODUCTION
Tenofovir (TNF), an antiretroviral drug, belongs to a drug class known as nucleoside blockers of reverse transcriptase (Chapman et al., 2003) , (Antoniou et al., 2003) AntonioChemically, TNF is described as [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid (Figure 1 ). TNF operates by blocking a vital enzyme, reverse transcriptase, which triggers viral replication in people infected with the human immunode iciency virus (HIV) . TNF is used in conjunction with certain other antiretroviral agents to treat infections caused by HIV and the hepatitis B virus (Ray et al., 2016) . Emtricitabine (ETC) is a synthetic nucleoside analog of cytidine with activity against type 1 HIV reverse transcriptase Emtricitabine (ETC) is a cytidine-like synthetic nucleoside of type 1 HIV reverse transcriptase activity (Molina and Cox, 2005) . ETC is de ined in chemical terms as 4-amino-5-luoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one( Figure 1 ). ETC has been authorized for usage in adult people with HIV infection in combo with certain antiretroviral agents. (Goicoechea and Best, 2007) ETC prevents replication of viruses through hindering type 1 HIV reverse transcriptase reverse behavior (Saravolatz and Saag, 2006) , (Mandal et al., 2017) Efavirenz (EVR) is an antiretroviral non-analog nucleoside and non-competitive inhibitor of reverse transcriptase (Vrouenraets et al., 2007) . EVR is de ined in chemical terms as (4S)-6-Chloro-4-(2-cyclopropylethynyl)-4-(tri luoromethyl)-2,4dihydro-1H-3,1-benzoxazine-2-one ( Figure 1 ). EVR is used in the diagnosis of HIV infections as an antiretroviral agent (Homkham et al., 2019) , (Maggiolo, 2009) . EVR is explicitly linked to the enzyme and restricts the operation of RNA and DNAdependent DNA-polymerase triggering degradation of the catalytic enzyme site (Mcdonagh et al., 2015) . ETC, EVR, and TNF combination are available as tablet formulation with the name Vonavir (Emcure Pharmaceuticals Ltd., India) (Vonavir tablets, 2019b) labeled claim of this (Vonavir tablets, 2019a) was 300 mg of TNF, 200 mg of ETC, and 600 mg EVR. The Vanover medication is meant for use in HIV-1 positive individuals who have been virologically repressed to their current antiretroviral treatment for more than 3 months (Deeks and Perry, 2010) , (Hodder et al., 2010) medication doesn't cure HIV but only prevents viral multiplication in the body. The Vonavir is not advised for use in children under the age of 12.
Few methods based on HPLC technique were reported to quantify ETC, EVR and TNF combination, (Devrukhakar et al., 2013; I H T Guideline, 2005) , (Ramaswamy and Dhas, 2018) , (Palavan et al., 2013) , (Rezaei et al., 2019) , (Raju et al., 2008) , (Varma et al., 2014) , Atlas et al. (2016) . UPLC is a signi icant laboratory technique that reduces costs and improves the analytical performance needed to develop and validate the process. UPLC method increases the speed of separation and improves ef iciency, resulting in the rapid development of approaches. UPLC method reduces solvent consumption and improves sample quality as well as providing real-time testing in line with production processes (Chawla and Ranjan, 2016) , (Babu et al., 2017) , (Tiwari et al., 2010) , (Kiran et al., 2017) , proposed methods based on UPLC technique. (Babu et al., 2017) method was mainly concerned with quanti ication of related substances in ETC, EVR and TNF combination. (Tiwari et al., 2010) method is not stability-indicating. (Kiran et al., 2017) method is stability-indicating, but this method uses gradient elution, which increases solvent consumption and analytical expense. Therefore, the current investigation is aimed at developing and validating a costeffective isocratic elution method using stability, indicating the UPLC technique to quantify ETC, EVR, and TNF combination in bulk and Vonavir tablets.
MATERIALS AND METHODS

Chemicals
The reference samples of ETC, EVR and TNF are obtained from M/s. Mylan labs Pvt. Ltd., India. Vonavir tablet (Emcure Pharmaceuticals Ltd., India) having 300 mg of TNF, 200 mg of ETC, and 600 mg EVR ixed dosage combination was purchased from the pharmacy market. The solvents used are UPLC grade, and the chemicals used are analytical grade. Acetonitrile, potassium dihydrogen phosphate, orthophosphoric acid, hydrochloric acid, hydrogen peroxide and sodium hydroxide were procured from M/s. Rankem Chemicals Ltd, India. All through the study, Milli-Q water was used, which is prepared with Milli-Q water system of puri ication (Millipore, Germany).
Instrumentation
The UPLC was carried out on Waters with empower 2695 separation module, autosampler, and PDA Detector. Labindia (Maharashtra, India) UV-Visible spectrophotometer was used for spectral measurements. The weighing was done on Afcoset (New Delhi, India) ER-200A, and pH meter Adwa (Szeged -Hungary) AD 1020 was used for adjustment of pH.
Chromatographic conditions
HSS C18 (100 × 3 mm, 1.7 µ) column was used for this study. The isocratic separation was achieved using 0.01 N potassium dihydrogen phosphate buffer (40% volume) with pH 4.5 and acetonitrile (60 % volume) combination as mobile phase. The mobile phase was degassed for 5 minutes in the ultrasonic water bath and iltered under vacuum iltering by 0.45 µ ilter. The mobile phase stream rate was maintained at 0.4 ml/min. The temperature of the column was held at 25 • C, and the quanti ication and detection were performed at 265 nm. Water and acetonitrile in the ratio of 50:50 (volume by volume) was employed as a diluent for preparing standard solutions. The injection volume was 5 µl.
Stock and working solutions of ETC, EVR, and TNF
The stock solution of TNF (3000 µg/ml), ETC (2000 µg/ml) and EVR (6000 µg/ml) was prepared as follows: Accurately weighed 300 mg of TNF, 200 mg of ETC and 600 mg of EVR are transferred into a 100 ml clean dry volumetric lask, and then 40 ml of diluent was added, sonicated for 10 min and made the inal volume to 100 ml with diluent. Calibration solutions of concentration range 75-450 µg/ml (TNF), 50-300 µg/ml (ETC) and 150-900 µg/ml (EVR) were prepared by proper dilution of stock solution (TNF -3000 µg/ml, ETC -2000 µg/ml and EVR -6000 µg/ml) with diluent. Working solutions of concentration 300 µg/ml (TNF), 200 µg/ml (ETC) and 600 µg/ml were prepared for validation study by proper dilution of stock solution (TNF -3000 µg/ml, ETC -2000 µg/ml and EVR -63000 µg/ml) with diluent.
Calibration curves of ETC, EVR, and TNF
Six calibration solutions of concentration range 75- 
ETC, EVR, and TNF degradation studies
ETC, EVR and TNF forced degradation was studied by degradation through exposure of tablet sample solution (TNF -300 µg/ml, ETC -200 µg/ml and EVR -600 µg/ml) to acid hydrolysis, oxidation, base hydrolysis, photodegradation and heat as follows (Guideline, 2003) 10 ml of tablet sam-ple solution was transferred to a 100 ml capacity volumetric lask. 10 ml of 0.1 N HCl was added, thoroughly mixed, and re luxed for 60 min at temperature 60 • C. The volume was accomplished to mark (100 ml) using diluent. The solution was iltered, injected into the HPLC system, and analyzed employed the conditions suggested. The same procedure was repeated with the addition of 10 ml of 0.1 N NaOH (for base hydrolysis) and with 10 ml of 30% peroxide (for oxidation degradation).
An accurately weighed portion of powdered sample equivalent to 200 mg of ETC, 300 mg of TNF, and 600 mg of EVR was exposed to 105 o C in the oven (to study thermal degradation) and direct sunlight for 6 hr (to study photodegradation). After the degradation period, the sample preparation and analysis were done as explained in section "Analysis of ETC, EVR, and TNF in Vonavir tablets."
In all conditions, the percent degradation and assay of ETC, EVR, and TNF were determined by comparison with the undegraded sample solution.
RESULTS AND DISCUSSION
Method development
Preliminary experiments included checking several mobile phase combinations for successful separation of ETC, EVR, and TNF on column HSS C18 (100 mm × 3 mm, 1.7 µ). Method development began with examining methanol combination with 0.01 N potassium dihydrogen phosphate buffer of pH 4.5 and acetonitrile combination with 0.01 N potassium dihydrogen phosphate buffer of pH 4.5 in isocratic elution. For the separation of ETC, EVR, and TNF, acetonitrile combination with potassium dihydrogen phosphate buffer has been effective.
Consequently, the same mixture was used in isocratic elution. Different ratios of acetonitrile and potassium dihydrogen phosphate buffer were examined. Good results were obtained with 0.01 N potassium dihydrogen phosphate buffer (40% volume) and acetonitrile (60% volume). Distinct pH values were examined. pH 4.5 was found as best because, at this pH, better separation of ETC, EVR, and TNF was achieved. Different low rates (0.3, 0.4, and 0.5 ml/min) were examined and observed that 0.4 ml/min was the good one. Ambient temperature was perfect for this separation and was therefore used throughout the process. Ultraviolet detection at 265 nm was utilized because it was discovered to be the optimum wavelength for ETC, EVR, and TNF. At this wavelength, it provided the ETC, EVR, and TNF elevated peak area. Using these conditions, good separation of ETC, EVR, and TNF with accept-
Figure 4: Photodegradation chromatogram
able peak shape, resolution, and sensitivity were obtained ( Figure 2 ).
Method validation
The procedure developed to estimate ETC, EVR, and TNF simultaneously has been validated for different parameters (I H T Guideline, 2005; Atlas et al., 2016) System suitability, linearity, speci icity, accuracy, robustness, precision, detection limits and quantitation limit.
System suitability
The parameters for system suitability (Tailing factor and plate count) were checked through analysis of ETC, EVR, and TNF solution at a concentration of 200 µg/ml, 600 µg/ml, and 300 µg/ml, respectively. The indings are noticed in line with ICH guidelines in the acceptance criteria (Table 1) .
Linearity
Linearity is found to be in the range of 75-450 µg/ml for TNF, 50-300 µg/ml for ETC, and 150-900 µg/ml for EVR. The correlation coef icient (R 2 ) values for ETC, EVR, and TNF are between 0.9989 and 0.9993.
The linearity graphs and regression equations of ETC, EVR, and TNF obtained are shown in (Figure 3 ).
Detection limit
The detection limit was assessed using a standard deviation of intercept in the regression equation (a) and slope of a regression equation (b). The below equation was employed to compute the detection limit.
The level of detection was 0.601 µg/ml for TNF, 0.330 µg/ml for ETC and 0.911 µg/ml for EVR.
Quanti ication limit
The quanti ication limit was also assessed using a standard deviation of intercept in regression equation (a) and slope of a regression equation (b). Equation to compute quanti ication limit was:
The level of quanti ication was 1.82 µg/ml for TNF, 1.00 µg/ml for ETC, and 2.76 µg/ml for EVR.
Precision
Six replicate injections of the same dilution (TNF -300 µg/ml, ETC -200 µg/ml, and EVR -600 µg/ml) are analyzed on the same day for verifying interday precision and on two different days for verifying inter-day precision. The relative standard deviation for ETC, EVR, and TNF peak areas were determined ( Table 2 and Table 3 ). Values less than 2.0% demonstrated excellent precision.
Accuracy
Recovery analysis using standard additional procedure was done for verifying method accuracy. The percentage of recovery investigation of ETC, EVR, and TNF has been achieved by spiking three varying quantities (50, 100, and 150%) of pure ETC, EVR, and TNF into the pre-analyzed tablet form. The recovery percentage of ETC, EVR, and TNF were calculated for each spiked level in three replicates. The percentage recovery outcomes (Table 4) demonstrated good accuracy and non-interference of excipients in the tablet.
Degradation study of ETC, EVR, and TNF
The study of degradation was performed by placing the tablet sample under stress conditions such as acid hydrolysis, base hydrolysis, oxidative degradation, thermal degradation, and photodegradation. This study was conducted to evaluate the stabilityindicating ef iciency and speci icity of the proposed procedure, and also the stability of ETC, EVR, and TNF under the conditions applied. (Table 6 ) outlines the results. The chromatograms of degradation studies are depicted in (Figure 4 a -e ). The order of stability of drugs in the applied conditions was:
1. ETC -sunlight > dry heat > HCl > NaOH > peroxide 2. TNF -sunlight > dry heat > HCl > peroxide > NaOH 3. EVR -sunlight > dry heat > peroxide > NaOH > acid
CONCLUSIONS
Easy and cost-effective stability-indicating isocratic UPLC method was established and validated for routine quantitative analysis of ETC, EVR, and TNF in the tablet dosage formulation. The method is stability-indicating and hence reliable and ef icient during stability studies to show and identify any predicted change or deterioration in the drug product. The method is suf iciently accurate, precise, and robust to reproduce results under various conditions of method.
